Perinatal HIV Testing Policy Development In Wisconsin by Rogers, Pamela F.
Perinatal HN Testing Policy Development 
In Wisconsin 
by 
Pamela F. Rogers 
07-May-2005 
A Master's paper submitted to the faculty of the University of North Carolina at Chapel 
Hill in partial fulfillment of the requirements for the degree of Master of Public Health in 
the School of Public Health, Public Health Leadership Program. 
Second Reader: William Williamson, MPH 
j_ 
1 
Abstract 
Most children with the human immunodeficiency virus (HIV) have been infected through 
transmission of the virus from their mothers either in-utero, at delivery, or through breastfeeding. 
In 1994, pharmacological treatment ofHIV-positive pregnant women prior to giving birth was 
shown to be effective in greatly reducing this transmission. Today, there is the potential for 
1,000- 2,000 HIV infected babies to be born each year in the United States. The Centers for 
Disease Control and Prevention (CDC) estimate that there are between 96,000 and 120,000 HIV-
positive women of childbearing age in the United States and approximately one-third do not 
know their HIV status. Research shows that women want to protect their unborn children and are 
willing to accept antiretroviral treatment to reduce mother to child transmission of the virus if 
found to be HIV -positive. Thus, while we may not be able to eliminate mother-to-child 
transmission ofHIV entirely, because of women who refuse treatment or testing, we can greatly 
reduce unrecognized births to HIV -positive women by increasing the numbers of women who 
are tested and know their HIV status. 
This paper will examine and recommend the best strategy to increase HIV testing 
of pregnant women to further reduce HIV infection in children born in Wisconsin 
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Introduction 
Mother to child (MTC) transmission is the primary route of HIV infection in young 
children. MTC transmission of the HIV virus generally occurs late in pregnancy, during delivery 
and through breastfeeding. 
The Pediatric AIDS Clinical Trial Group (PACTG) 076, published in 1994 showed that 
giving zidovudine (ZDV) to HIV-positive women during pregnancy and labor and to their 
infants after birth reduced the rate ofHIV transmission from 25.5% to 8.3% (Couner, Sperling, 
Gelber, 1994). Through advances in medical management and treatment we now have the 
opportunity to further reduce HIV disease in infants, but in order to do so HIV must first be 
detected in pregnant women through testing. 
HIV infection occurs in all regions of the state of Wisconsin. Between 1990 and the end 
of October 2004 there have been 79 pediatric cases of HIV reported (Wisconsin HIV I AIDS 
Quarterly Surveillance Summary, 2005). Figure 1 shows the number of HIV positive infants 
born in Wisconsin between 1982 and 2003. While the numbers ofHIV infected infants have 
been declining since its peak in 1990, babies are still being born with perinatally acquired HIV L 
Figure 1. HIV Pos~ive Infants by Year ol8irth, Wisconsin 1981-2003 
infection. Review of the data for recent years has 
shown decline from an average of 6.5 HIV infected 
babies being born between 1990 - 1993, to an 
average of 2.3 HIV infected babies being born 
between 2000 and 2003 (Schell, Steenberg, Hoxie, 
""' 1033 19SS 1007 1009 , .. , ,.., .... 1997 , .... 2CXl1 = 2003). Between 2000 and 2003 eleven infected 
Year of birth 
infants have been born to HIV positive mothers residing in the State. Because most women want 
to protect their children from illness and disease (AIDS Alliance for Children, Youth & Families, 
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2004), the fact that babies are still being born with HIV suggests that pregnant women are not 
receiving HIV tests and do not know their HIV status. In order to encourage HIV testing among 
pregnant women to we need to look at the current approaches to perinatal HIV testing to 
understand what strategies work and if others are needed in Wisconsin. 
Surveillance data indicate that there is a greater HIV seroprevalence among women of 
childbearing age in Milwaukee County. However, since 1996 the number of infants born 
outside of Milwaukee County to HIV-positive women has increased. Table 2 includes Wisconsin 
metropolitan statistical areas (MSAs) by population and HIV incidence among women of 
childbearing age for the year 2000 and Table 3 shows the numbers of infants born with HIV 
infection as of July 2002. 
Table 2. Wisconsin MSAs by population and HIV prevalence for the year 2000 (Hoxie, Conway, Vergeront, 2002) 
Coun!}' /MSA Poeulation HIV cases!al 
N % N % Rate (b) 
Milwaukee MSA 1,500741 28 88 59 2.9 
Dane County MSA 426,526 8 21 14 2.5 
OtherMSA 1,676,237 31 30 20 0.9 
Non-metropolitan counties 1,760,171 33 11 7 0.3 
Total 5,363,675 100 150 100 1.4 
(a) HIV cases reported between 2000 and 2001 among women 15-45 years of age. (Wisconsin AIDSIHIV Program HIV cases surveillance data) 
(b) Average annual cases reported between 2000 and 2001 among women 15-45 years of age, per 100,000 population. 
Table 3. Infants born with HIV infection in and outside of Milwaukee (July 2002) (Hoxie, Conway, Vergeront, 2002) 
Total number of infants born to women with 
HIV infection 
Number of infants infected with HIV 
% of infantS infected with HIV 
P-Value 
In 
Milwaukee Outside Milwaukee 
Before 19% 1996-2002 Before 19% 1996-2002 
74 
18 
24% 
0.0008 
87 
5 
6% 
15 
5 
33% 
0.07 
47 
6 
13% 
Between January 1, 2000 through December 31, 2003, Wisconsin surveillance data 110 
infants were reportedly born to HIV infected women (Schell, Hoxie, Steenberg, 2005). Of those 
infants, 11 were born with perinatally transmitted HIV infection, including one set of twins 
(ninety-four where HIV-negative, and 5 were lost to follow-up). Of the ten mothers who gave 
birth to the 11 HIV -positive infants, four mothers were reported from Milwaukee County, one 
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from Dane County, three from the remainder of the State, and two mothers had moved to 
Wisconsin and their infants were tested for HIV shortly after giving birth. The underlying 
factors in perinatal HIV infection transmission for the HIV positive infants born during that time 
period include no or very late prenatal care, inadequate treatment or non-compliant treatment 
(e.g. never told results and not treated; patient did not comply with treatment regimen). 
Pre-natal care providers in Wisconsin follow national trends by supporting the concept of 
universal HIV testing of pregnant women· and when asked, providers echo similar reasons for not 
offering an HIV test as providers in other parts of the United States. These data are supported in 
Wisconsin by provider surveys conducted in 1992, 1996, and 2002, which assessed Wisconsin's 
physician attitudes regarding perinatal HIV testing (Hoxie, Conway, Vergeront, 2002; Wisconsin 
AIDS/HIV Program, 1993; Wisconsin AIDSIHIV Program, 1996). For each of the three years 
selected, these self-administered surveys sent to 1,000 providers randomly selected from among 
1,357 general, family and obstetrics/gynecology practice physicians who reported being prenatal 
care providers on a Physician Profile Survey conducted by the Office of Health Care 
Information, Wisconsin Department of Health and Social Services (currently Wisconsin 
Department of Health and Family Services). The survey selection process also included 131 
nurse practitioners identified as prenatal care providers from a Wisconsin Nurses Association 
membership survey. In addition to collecting general demographic and practice information, the 
questionnaire asked for information concerning attitudes toward and the availability of HIV 
prevention-related services to prenatal care patients in three areas - HIV prevention education, 
HIV risk assessment and HIV antibody testing. In the latest survey, conducted in 2002, 97% of 
the providers either agreed or strongly agreed with the statement "In my community HIV testing 
should be offered to all pregnant women." Most pre-natal care providers (87%) reported that 
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they offer universal HIV testing to pregnant women in their practice, however, a review of post-
delivery medical charts indicates a lower percent of women recalling that they had been offered 
an HIV test by their pre-natal care provider. To assess the level of prenatal HIV testing in 
Wisconsin from the woman's perspective, the AIDS/HIV Program selected a random sample of 
1,000 births from 2003 Wisconsin birth certificate data. For each birth, a data collection form 
was mailed to the infection control professional (ICP) at the birth hospital. The data collection 
form instru<.:ted hospital staff to provide only information regarding completion of HIV antibody 
testing and not to provide the results of any HIV test. The ICP was asked to review the maternal 
hospital medical record, complete the data collection form and return it to the survey coordinator. 
Requests were sent to 95 Wisconsin hospitals and ninety hospitals responded with a review of 
968 birth records. Sixty-eight percent of the medical records reviewed indicated that the mother 
had completed an HIV antibody test during pregnancy. The reasons for the difference in the 
numbers of pregnant women being tested for HIV and the actual numbers of women being tested 
need to be investigated. Providers often list the following reasons for not offering an HIV test to 
pregnant women: they do not believe their patient to be at risk (37%); they believe their patients 
to have been previously tested for HIV (19%); the time required for counseling and/or obtaining 
informed consent (11%); and confidentiality concerns (3%). Implementation of universal testing 
was less frequent in non-metropolitan areas and non-OB/GYN practice groups. Acceptance of 
HIV testing was higher if providers strongly recommended or encouraged acceptance of testing 
for all pregnant women in their practice, and discussed a woman's initial decision to decline HIV 
testing with her. 
Currently in Wisconsin there are no specific laws or mandates regarding perinatal HIV 
testing. A Kaiser Family Foundation survey indicates that prenatal care providers in Wisconsin 
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follow the CDC guidelines of voluntary HIV -testing, with counseling the requirement of 
informed consent. The Wisconsin Association for Perinatal Care in their Position statement on 
HIV testing in the Perinatal Period (January 2002) recommend that: 
• 
• 
All pregnant women should be provided with culturally, linguistically, educationally, and 
age-appropriate information regarding HIV prior to testing; 
All pregnant women should be offered and encouraged to accept voluntary HIV antibody 
testing early in pregnancy. This may be repeated at 36 weeks for select women; 
• Women in labor should be encouraged to accept voluntary HIV antibody testing if their HIV 
serostatus is unknown. 
• 
• 
If HIV testing prior to delivery cannot be documented, postpartum HIV antibody testing of 
the mother, cord blood or infant blood with the mother's consent should be strongly 
encouraged. 
For infants whose HIV exposure status is unknown at the first health supervision visit, 
assessment of the mothers HIV status or HIV testing of the infant is appropriate. 
However, the discrepancy between the provider surveys and the chart review seem to suggest 
that in reality providers may not follow these recommendations. Additionally, surveillance data 
show that MTC transmission ofHIV still occurs. 
Historical Perspective of Perinatal HIV testing 
Prior to 1994 
Initially in the history ofHIV infection, knowledge about HIV infection during 
pregnancy was scarce. HIV disease was thought to be strictly a disease of gay men. Evidence 
gained anecdotally suggested that women were infected and about one-third of babies born to 
women who were HIV -positive prior to pregnancy would acquire the infection. At that time it 
was unknown if pregnancy might accelerate the progression from HIV to AIDS in the mother, 
especially of those who were asymptomatic. Early in the epidemic there was no available 
treatment for anyone with HIV disease. The general consensus was that once an HIV -positive 
woman was pregnant there was nothing further that could be done except to end the pregnancy. 
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The greatest opportunity for prevention of perinatal HIV infection at this time was finding 
women prior to pregnancy who were at risk of contracting the disease through counseling and 
testing programs. HIV testing of pregnant women was generally not done at this time because: 
• There was no known treatment for HIV disease in pregnant women; 
• Pregnant women felt threatened by being identified as having "risk"; and, 
• Fear of pregnancy termination because of being found HIV-positive discouraged women 
from seeking prenatal care. 
After 1994 
In 1994 researchers at the US National Institutes of Health (NIH) and its collaborators 
announced the interim results from ACTG 076, a study of the effects on ziduvodine (ADV) to 
reduce MTC transmission. The interim results showed that the antiretroviral medication ZDV 
provided to pregnant women during pregnancy, labor, and delivery and to the newborn during 
the first six weeks of life could dramatically reduce the risk of MTC transmission of HIV 
infection. Other studies have since confmned these results or achieved even better results 
(Cooper, Nugent, Diaz, 1996; Blatner, Cooper, Charurat, 2000; Lallemant, Jourdain, LeCoeur, 
2000) 
The US Public Health Service (PHS) responded to the interim results with 
recommendations that health care providers consider the therapy outlined in the ACTG 076 
study to all HIV positive pregnant women meeting the entry criteria for the study. The PHS 
further recommended that specified components of the ACTG 076 regimen be discussed with 
and in some cases recommended to women presenting clinical characteristics more removed 
from the original entry criteria. Pregnant women not meeting the study criteria, such as those 
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with advanced HIV disease, low CD4 counts, or prior antiretroviral therapy, be excluded because 
the risks to those women were not yet known. 
In 1995, the PHS altered its HIV testing recommendations for pregnant women from a 
targeted "at risk" approach to universally calling for counseling all pregnant women about HIV 
infection and then encouraging them to be tested for the disease. This shift in approach was 
attributed to both the advances in prevention interventions and the treatment ofHIV with ZDV. 
In 2001 the PHS again updated the recommendations founded on the results of the ACTO 
076 study. These recommendations acknowledged the effectiveness of the ACTO 076 regimen 
not only in those meeting the study criteria, but also confirmed the effectiveness of the ACTO 
076 therapy regimen in other populations of women with HIV. This is the basis of the current 
standard of care in treatment of HIV infection in the United States. 
Now that a treatment regimen proved successful for greatly reducing MTC transmission 
of HIV the main barrier to elimination of HIV in infants was getting a pregnant woman to be 
tested. In the 2001 revision of the PHS guidelines for HIV in pregnant women recommendations 
for their care included that all pregnant women in the United States be tested for HIV infection 
and that HIV screening should be a routine part of prenatal care. It was further recommended 
that for those who do not access prenatal care prior to labor and delivery, HIV testing should take 
place at labor and delivery and if the woman was found to be HIV -positive the appropriate 
chemoprophylaxis should be administered to both the woman and the newborn. 
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Perinatal HIV Testing 
Many HIV test strategies for pregnant women have been discussed in the United States 
and the World. These strategies range from purely voluntary, where the decision of an HN test 
lies with either the pregnant woman or her care provider, to strictly mandatory, where laws, 
statutes, or administrative code requires a pregnant woman or her newborn to undergo HIV 
testing. Understanding the subtle differences in strategies is key to developing perinatal HIV test 
recommendations for Wisconsin. A logical discussion of the perinatal HIV testing strategies 
available, from identifYing how HIV tests can be offered to pregnant women, and examining 
issues of consent and timing, is outlined below and follows. Table 4 contains an outline of these 
strategies. 
Table 4. Outline of Perinatal HIV Test Strategies 
I. Approach 
A. No Testing 
B. Selective Testing 
1. Test those at risk 
2. Test those in high prevalence 
areas 
C. Universal Testing 
II. Offer 
A. Voluntary 
B. Mandatory 
1. Conditionally mandatory 
a) immigration 
b) care 
2. Required by law 
Ill. Consent 
A. Opt-in 
B. Opt-out 
C. No consent 
IV. Schedule 
A. Early in care 
B. Late in care 
C. Labor and delivery 
D. Newborn 
I. Approach 
There are four basic strategies to HIV testing of pregnant women. One is to do nothing, 
another is a purely voluntary approach where a woman must ask for an HIV test, another is the 
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selective approach of testing women who are most likely to have an HN infection, and yet 
another is to test all pregnant women for HIV infection. 
A. No testing 
Physician responsibilities: None 
Patient responsibilities: None 
Advantages: Physicians and patients do not have to take the time to be 
tested. No costs are involved. 
Disadvantages: Women do not find out their HIV status and would not be 
offered treatment if found to be HN -positive. Babies may be born with 
HIV infections. 
Approach recommended by: This approach is not endorsed by any 
professional organization or State, although some care providers may use 
it. 
States who uses this approach: Unable to assess. 
Does it work: No 
B. Selective Testing 
1. Test those at Risk 
In this type of approach only certain individuals are targeted for HN testing. 
Criteria used to target these individuals for testing are based on a risk assessment 
of the women for HIV infection. The most frequent questions asked to assess 
HIV risk include the use of intravenous drugs, sex with an intravenous drug user, 
sex with a man who has sex with men and sex with someone who is HIV -positive. 
Physician responsibilities: Providers must define risk and provide risk-
assessment screening in order to determine the HIV risk status of the 
patient. If the woman is found to be HIV -positive the provider must have 
in place a system for referral to treatment. 
Patient responsibilities: Patient must obtain prenatal care. Patient must 
understand information about HIV risk factors and truthfully answer the 
assessment questions. Patient must return for their test result and if found 
to be HIV -positive the patient must obtain and participate in treatment. 
Advantages: HIV testing based on assessed risk appears to be cost-
effective. However, because of the greater possibility of missing an HIV-
positive woman who was not identified as having risk, costs may actually 
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be higher because the life-time costs of treating an infected infant missed 
by this strategy is high. 
Disadvantages: Women may choose not to have an HIV test even they 
may have risk. The provider must make the decision of who is at risk and 
who is not, often based is based on provider opinion and may be biased. 
Testing strategies that are targeted only to women who report high-risk 
behaviors fail to identify as many as 50%-70% of infected women. 
Approach recommended by: Prior to the 2001 CDC recommendations for 
perinatal testing their recommendation was to only offer HIV tests to those 
considered to be at risk. In 2001 the CDC reassessed this strategy and 
currently there are no professional organizations who recommend this 
approach. 
States who uses this approach: No states who use this approach of testing 
only pregnant women determined to be at risk. 
Does it work: An article printed in the CDC's November 9th, 2001, 
Morbidity and Mortality Weekly (MMWR) states that risk-based 
voluntary testing approaches identified fewer HIV -infected women than 
universal testing of all pregnant women. Because there are no states 
currently using this strategy, there is no new data to support its use. 
2. Test those in high Prevalence Areas 
This approach relies on HIV surveillance data and targets testing to all 
pregnant women who reside in limited geographic areas with high seroprevalence, 
or who are members of racial or ethnic groups disproportionately affect by HIV. 
Physician responsibilities: Provider must define high-prevalence and 
decide on geographic areas to be considered then consistently test 
pregnant women from those areas. 
Patient responsibilities: Patient must obtain prenatal care. If a patient has 
moved outside of a high prevalence area they must report this to their 
provider. Patient must return for result after being tested. Patient must 
participate in appropriate care and treatment if found to be positive. 
Advantages: This target approach it is likely to be cost effective since it 
may detect a higher percentage ofHIV-positive woinen. 
Disadvantages: Risk criteria may differ by provider since the provider 
defines seroprevalence levels. A woman may not be truthful in her 
disclosure of residence or other selection criteria. 
Approach recommended by: Early in the epidemic this approach was 
promoted as being very cost-effective. However, today no professional 
organizations recommend this approach because of the potential for 
discrimination and stigmatization of already disenfranchised or 
disadvantaged populations. 
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States who uses this approach: No states who use this approach. 
Does it work: Because there are no states currently using this strategy, 
there is no new data to support its use. 
C. Universal Testing 
In a universal approach to HIV testing, all pregnant women would receive an HIV test 
as part of their prenatal care. 
Physician responsibilities: The provider must have a system in place for 
HIV testing of their patients. If found to be positive, the provider must 
either refer patient fm treatment or provide treatment. 
Patient responsibilities: Woman must be informed about HIV disease its 
risk to and effect on her unborn infant. Woman must evaluate 
implications of receiving an HIV test. If found to be HIV -positive, the 
woman must accept and adhere to treatment. 
Advantages: All women could potentially be tested for HIV, therefore, a 
greater number ofHIV-positive women would be detected and treated. 
Universal HIV testing could reduce stigma since some women would not 
be singled out because of risk. 
Disadvantages: Cost savings varies by geographic and prevalence area. 
Women may feel this violates their civil rights. Women who are HIV-
positive may avoid prenatal care 
Recommended by: The American Academy of Pediatricians (AAP) and 
the American College of Obstetricians and Gynecologist (ACOG) in both 
1995 and 1997 recommended this approach. In 1995 the AIDS Alliance 
for Children, Youth and Families called for universal, voluntary testing to 
be done routinely as a component of prenatal care. 
States that use: Providers in Michigan, Texas, Tennessee, and New 
Mexico are required by law to conduct an HIV test on all women unless 
the woman objects. 
Does it work: The acceptability of this approach is high. Sixty-three 
percent of pregnant women surveyed liked the idea of universal routine 
perinatal HIV testing (Sengupta and Lo, 2003). 
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II. Offer 
A. Voluntary 
The care provider does not offer counseling on HIV infection or offer HIV testing. 
This is a completely voluntary approach where the pregnant woman must specifically 
request an HIV test. 
Physician responsibilities: The physician does not have any responsibility 
to offer pregnant women information on HIV disease or HIV testing. 
Patient responsibilities: The pati~nt bears all responsibility to educate 
herself on HIV disease, the effect of the disease on her infant and herself, 
and the process to get tested for the disease. The patient must then 
approach her caregiver and specifically ask to receive an HIV test. 
Advantages: Care providers save time by not providing information on 
HIV that is already readily available. This time can be spent on direct 
patient care. It is up to the patient to decide if they have risk that would 
justify taking an HIV test. 
Disadvantages: Women must know about HIV, assess their risk for the 
disease and, make the final decision to request an HIV test. HIV positive 
patients may not request the test because of lack of knowledge of the 
disease, lack of perceived risk for the disease or because of stigma. There 
is no accountability or evaluation of the strategy. Care providers may not 
be consistent in their approach- sometimes offering and sometimes not. 
In 1998 an IOM study concluded that continued perinatal transmission of 
HIV was mainly caused by a lack of awareness of HIV among some 
pregnant women. This problem was attributed to some healthcare 
providers not offering HIV information and/or testing. 
Recommended bv: If care providers choose not to inform women about 
HIV disease, its effect on their unborn child, testing and treatment, the 
value of perinatal HIV testing can be lost. Therefore, no professional 
organizations currently recommend this entirely voluntary approach that 
relies only on the pregnant woman. 
States that use: While a majority of states use a voluntary approach, most 
are based on some recommendation or policy. There are only three states, 
Idaho, Kansas and Vermont, who have neither laws nor policies on 
counseling and testing of pregnant women leaving it entirely up to the 
patient to request an HIV test. 
Does it work: Because of the voluntary nature of this strategy, no records 
have been kept or analyzed to determine the success of this strategy. 
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B. Mandatory 
Mandatory testing as used here means that there is a law or requirement which 
conveys an obligation to do something. This requirement is legally binding and has 
penalties for failing to take action. This requirement is enforced by domestic, 
international courts, or oversight organization. 
Eighteen states have laws that specifically address prenatal HIV testing. These states 
take a variety of approaches. Five states do not apply special HIV testing requirements 
for pregnant women, but use their general HIV testing requirements for pretest 
counseling and or informed consent. Three states require prenatal care providers to give 
their patients information about HIV testing with no requirement to offer testing. Two 
states require HIV information and/or testing to be offered to pregnant woman with 
certain risk factors. Seven states require health care providers involved in prenatal care 
to offer HIV testing to all their pregnant patients although testing cannot proceed without 
explicit consent. Eight states require HIV testing of every pregnant woman unless she 
objects to testing. 
1. Conditionally Mandatory 
In a conditionally mandatory testing program either the government, a private 
institution or professional organization makes access to or the provision of 
services contingent upon participation in testing. Some examples of a 
conditionally mandatory testing strategy follow. 
a) Immigration. As a condition of immigration, all pregnant women coming 
into the United States must have been or must be tested for HIV. 
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Physician responsibilities: Caregivers, from both the country of origin and 
the United States, must be available to perform an HIV test. Caregivers 
must have knowledge of what is required for immigration and have the 
proper forms. Caregivers from the country of origin must collaborate with 
caregivers in the United States. Caregivers & immigration officials must 
take the opportunity to enroll those that need care with providers. 
Patient responsibilities: Patient must be in care in order to obtain an HIV 
test. Patient must have knowledge about immigration requirements. 
Advantages: Pregnant women entering into the United States will have 
access to care. If found to be HIV -positive, pregnant women will be 
referred to access treatment. 
Disadvantages: This strategy may encourage those seeking residency in 
the United States to enter illegally to avoid testing. Testing may have 
been performed too early to detect the antibodies or a woman may acquire 
the infection after entering the country. Requires caregivers in both 
countries to communicate. Seen as a violation ofrights. Language and 
cultural barriers. 
Recommended by: There are no organizations or states that recommend 
this strategy. However, for immigration to the United States and to Canada 
requires that an HIV test be administered to anyone 15 years of age or 
older. 
States that use: No States have laws that require an HIV test for 
citizenship in that state. 
Does it work: In Canada, the majority of infants born with HIV are born to 
mothers who have immigrated recently, to those who have not immigrated 
legally or to those who have not had prenatal care or have entered into 
care late. 
b) Care provision. As a condition of prenatal care provision in a State, the 
provider would be required by law to offer an HIV test either to all pregnant 
women or women at risk for HIV disease. 
Physician responsibilities: Caregiver must test for HIV 
Patient responsibilities: Patient must seek prenatal care. Patient must take 
HIV test. 
Advantages: Providers are required to have a discussion about HIV with 
their potential patient. 
Disadvantages: Possible violation of patients rights. May deter patients 
from seeking prenatal care. Possibly cost -ineffective since all patients 
would be tested. 
Recommended by: No professional organizations or states recommend this 
approach. However, one state, Kentucky, ties funding to State Prenatal 
Clinics contingent on testing for HIV. 
States that use: Only Kentucky uses a variation of this contingency by 
tying funding to state prenatal clinics to the requirement of including HIV 
testing as part of a routine prenatal laboratory work up. 
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Does it work: While the numbers ofHIV infected infants being born has 
gone down in Kentucky, there is no specific data to suggest that this is due 
to the use of this strategy (The Hemy J. Kaiser Foundation, 2002). 
2. Required by Law 
In a completely mandatory approach state laws are enacted that require some 
action. If this action is not done, sanctions can be taken. Some states have written 
laws that require providers to conduct an HIV test on all pregnant women, while 
some states require HIV testing be done on only those pregnant women who 
exhibit risk factors. Other state laws require only that providers offer an HIV test. 
Some States mandate that newborns be tested for maternal HIV-antibody with or 
without the mother's consent, if the mother's HIV status is unknown at delivery. 
Physician responsibilities: Provider must be informed on the law. 
Provider must have the capability in their care setting to perform an HIV 
test, or to refer to a site that does this testing. Providers must also keep a 
record of who has had the test and the test results. If the woman is found 
to be positive for HIV, the provider must either refer them to treatment or 
provide the treatment. 
Patient responsibilities: A woman must be in care. If found to be positive 
a woman must accept and adhere to treatment. 
Advantages: Since HIV testing is mandatory increased numbers of women 
with HIV infection will be found. Any woman who is or has been 
pregnant will know her HIV status. Stigma may be reduced because 
everyone receives HIV testing. 
Disadvantages: Women may avoid prenatal care because they have risk 
factors or object to the social or legal implications. A woman who tests 
positive unexpectedly may suffer adverse mental anguish and possibly 
physical retribution. HIV tests can produce false positive results. 
Recommended by: Currently there are no professional organizations that 
endorse mandatory HIV testing of pregnant women. Some states, 
however, have created laws that require a prenatal care provider to 
conduct an HIV test unless a woman objects. This opt-out strategy 
combines both the mandate of testing by law with the option of declining 
the test by the woman. 
States that use: There are no states that require an HIV test of pregnant 
women without the possibility of the woman refusing the test. However, 
Michigan, Texas, Tennessee, New Mexico, and Arkansas require that an 
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HIV test be conducted while allowing the option of a woman to refuse the 
test. 
Does it work: Since there are not states that require HIV tests of pregnant 
women, there is no data to support this strategy. 
III. Consent 
A. Opt-in Testing 
In this type of program individuals are provided information about the test, and the 
choice about whether to be tested is left to completely to them. Patients must actively 
choose to be tested, and if they do not 'opt-in' to be tested, the default is that no testing 
will occur. This type of program calls for HIV testing to be offered to all pregnant 
women irrespective of the presence or absence of identified risk factors for HIV 
infection. Women are provided with pre-test counseling and must specifically give 
consent to the test, usually in writing. Since this is essentially voluntary testing, there are 
no laws or requirements to follow, however, this voluntary approach is outlined in CDC 
guidelines. In both 1995 and 2001 the CDC recommended universal HIV counseling and 
voluntary HIV testing for all pregnant women. This recommendation continues today. 
This latest recommendation states that HIV testing of pregnant women and infants should 
be voluntary, providers must obtain informed consent for testing as required by their state 
laws, and state or local laws and regulations governing HIV testing should be followed. 
Health care providers should recommend HIV testing to all of their pregnant patients, and 
HIV screening should be a routine part of prenatal care for all women, however, women 
may refuse the test and should not be tested without their knowledge. When a woman's 
HIV status is unknown at labor the CDC recommends rapid HIV testing, with patient 
notification and the right of refusal. Most States currently follow this approach. 
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Physicians responsibilities: Care provider must counsel or give 
Information on HIV to all pregnant women early in their pregnancy and 
then offer an HIV test. If the woman accepts HIV testing the test result 
must be documented in her chart. If the woman tests positive, she must be 
treated or referred to treatment. 
Patient responsibilities: Patient must seek prenatal care. Patient must 
understand HIV information given to them. Patient must accept testing. If 
found to be positive, patient must accept and adhere to treatment. 
Advantages: Since all women are offered an HIV test, there is no need to 
distinguish between those at risk and those not at risk. Because the 
woman does not need to disclose any risk factors the doctor patient 
relationship is intact. Stigma is lessened because all women are tested. 
There is a lower chance of some HIV -positive women not being detected. 
Since the final decision lies with the woman, the woman still retains the 
right to opt-in or choose to be tested, thus preserving her constitutional 
rights. 
Disadvantages: Because this strategy is still completely voluntary for 
both the provider and the woman, the physician may choose not to even 
offer testing. Additionally, if the provider does not deliver pre-test 
counseling the woman may not be fully informed of her rights, and the 
process for HIV testing. Because there is no enforcement mechanism, the 
woman has no recourse if her confidentiality is breached. Women state 
confidentiality concerns such as her spouse finding out and stigma within 
the community if she decides to be tested. 
Recommended by: Many professional organizations recommend this 
voluntary, universal approach. In 2001 the Centers for Disease Control 
and Prevention (CDC) revised their 1995 recommendations to include the 
voluntary testing of all pregnant women, not just those at risk. The latest 
recommendation states, "the HIV testing of pregnant woman and infants 
should be voluntary, providers must obtain informed consent for testing as 
required by their state laws, and state or local laws and regulations 
governing HIV testing should be followed. Health care providers should 
recommend HIV testing to all of their pregnant patients, and HIV 
screening should be a routine part of prenatal care for all women, 
however, women may refuse the test and should not be tested without their 
knowledge. Other professional organizations recommending variations of 
this strategy include the National Medical Association, the American 
Medical Association, and the Association of Women's Health, Obstetric 
and Neonatal Nurses. The American College of Nurse Midwives and the 
National Governors Association also recommend this strategy, but place 
additional emphasis on improving access to early prenatal care. 
States who use this approach: Thirty-two of the fifty United States use 
this opt-in strategy and offer an HIV test to all pregnant women. Most of 
these states follow the latest CDC recommendations. 
Does it work: When offered HIV testing approximately 70% of all 
pregnant women will accept.(CDC, 2001) 
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B. Opt-out testing 
Under the opt-out approach, women are notified that an HIV test will be included in a 
standard battery of prenatal tests and procedures. In addition to a test for HIV antibodies, 
other routine screenings for infection, such as hepatitis B and syphilis, will be included. 
The care provider should inform the woman that testing is considered routine and there is 
no need for formalized counseling or written informed consent. A woman can decide not 
to have (opt-out) of one or all tests. Unless the woman specifically declines the test, the 
test will be performed. 
Physician responsibilities: Care provider must inform the patient that an 
HIV test is included in the prenatal testing panel. If counseling is to be 
given, the caregiver must take the time to explain the test. If written or 
informed consent is to be given, the provider must obtain this. Provider 
must record results in chart. Provider must ensure an HIV -positive 
woman care and treatment for her disease. 
Patient responsibilities: Woman must be in prenatal care. Woman must 
gather and understand information on HIV. Woman must follow-up to 
receive result. If positive, the woman must understand its implication and 
seek treatment. 
Advantages: If the default is to perform an HN test, this strategy would 
test the most women and likely find the most infections. 
Disadvantages: Women, especially those with risk factors, may avoid 
prenatal care. Women may elect to opt-out. The cost of testing everyone 
may be cost-prohibitive for some jurisdictions or care settings. If this cost 
is passed on to the patient, she may avoid care. 
Recommended by: The CDC and many professional organizations 
currently recommend this strategy. Most Canadian provinces use this 
approach. 
States that use: Michigan, Texas, New Mexico and Arkansas all require 
care providers to test their pregnant patients for HIV unless the patient 
specifically opt-out. 
Does it work: The CDC reports a high rate of acceptance (85% - 98%) of 
perinatal HIV testing with this opt-out approach (CDC, 2004). 
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C. No consent 
IV. Schedule 
Phvsician responsibilities: Care providers would not be responsible for 
obtaining consent. 
Patient responsibilities: the patient must on their own seek answers to the 
implications, consequences, barriers and benefits to obtaining an HN test. 
Advantages: Not obtaining consent may save time for care providers. 
The time saved may be translated into additional care for the patient. 
Disadvantages: Since neither verbal nor written consent to test takes 
place, some have argued that there is a violation of a patients civil rights. 
Additionally, because the right to refuse is not offered, a pregnant may 
avoid prenatal care altogether. 
Approach recommended by: No professional organizations recommend 
this strategy. However, there is recognition that HIV testing does occur 
without a woman's consent. In 1995 a study of hospital charts and birth 
records in the United Kingdom showed that of those women offered an 
HIV test during pregnancy, 15% did not have documentary evidence of 
giving consent. (Dalzell,Farkas, Hawken, Hudson, 1995) 
States who use this approach: No states explicitly use this strategy, 
although one state, Alabama, permits HIV testing without consent if the 
physician determines that the test is necessary because results may alter 
care. (Code of Alabama, 2003) 
Does it work: While there has been a reported increase in perinatal HIV 
testing in Alabama when this strategy is used, its effectiveness is difficult 
to assess. However, among patients, a sixty-six percent raised concern 
about no consent (Sengupta and Lo, 2003) 
The timing ofHN testing of pregnant women is something to consider. If tested early in 
a pregnancy, by the time the baby is born the woman may have turned positive because 
she had not yet seroconverted to produce antibodies to HIV or she may have contracted 
HIV during her pregnancy by continuing risky behaviors. Additionally, some women 
may not be in routine prenatal care or have recently moved or immigrated. When is HIV 
testing most likely to identify an HIV positive woman and enough time for prophylaxis 
and treatment. 
21 
A. Early in care 
Phvsician responsibilities: Care provider must consistently test for HIV at 
a woman's first prenatal appointment. 
Patient responsibilities: Woman must enter into prenatal care early in her 
pregnancy. 
Advantages: Early testing for HIV ensure that treatment is offered and 
started to a woman found HIV -positive prior to delivery protecting both 
the health of the mother and the health of the baby. 
Disadvantages: If an HIV test is offered only once, early in pregnancy, 
some cases may be missed because the woman be in the early stages of 
infection where antibodies can not be detected or a woman may continue 
risk behaviors and become infected later in her pregnancy 
Approach recommended by: The Wisconsin Association for Perinatal 
Care recommends HIV testing during a woman's first prenatal care visit. 
States who use this approach: Arkansas and Tennessee recommend 
perinatal HIV testing as early as possible and Connecticut recommends 
testing both at a woman's fust prenatal care visit and again during the 
third trimester. The CDC guidelines proposed in 1995 recommend HIV 
testing early in care and ifthe results are not documented in her medical 
chart, testing should be done during labor and delivery. 
Does it work: While testing early in pregnancy works, there are some 
cases that are missed. Women infected with HIV may be at particular risk 
of delaying or not receiving prenatal care. In one study of 4 states, 14% of 
HIV infected women received no prenatal care and 23% started receiving 
prenatal care in the third trimester (Mofenson, 2000) 
B. Late in care 
Physician responsibilities: Care provider must assess whether the woman 
has had an HIV test previously done. If not, or if the test has been 
declined, provider must offer testing. If a woman is found to be HIV-
positive provider must discuss pregnancy precautions and treatment 
options with the woman or refer her to another provider for HIV care. 
Patient responsibilities: Woman must have knowledge ofHIV and testing 
implications. If found HIV -positive woman must seek and adhere to 
treatment. 
Advantages: By testing closer to delivery, an HIV test is more reflective of 
the infant's HIV status. Late testing also eliminates the need for multiple 
HIV test, such as one during the first care visit and another later in the 
pregnancy. This approach may provide an HIV test result for those who 
enter prenatal care late in their pregnancy. 
Disadvantages: One objective ofHIV testing is to maximize the benefits 
of treatment if a woman is found to be HIV -positive. The benefits of 
22 
treatment are greater if the time spent on treatment is lengthened. If tested 
and found to be positive late in the pregnancy, treatment time is shortened. 
Approach recommended by: No professional organizations recommend 
this as a single strategy, many, such as ACOG and the Public Health 
Service, recommend it in combination with an HIV test during the first 
visit. 
States who use this approach: In the United States, there are no states 
offering an HIV test late in pregnancy as the only HIV test. Most states 
offer an HIV test at the first prenatal visit and again in the third trimester 
of pregnancy. In Canada, the Northwest Territories recommend an HIV 
test in the second trimester (Northwest Territories Health and Social 
Services, 1996) 
Does it work: While there are no states that have researched at what stage 
of pregnancy a woman would prefer and accept and HIV test we can make 
some comparisons by looking at when a woman enters into care. Recent 
data gathered by the Wisconsin Bureau of Family and Child Health 
identified that 59.4% of women initiated care in the first trimester in 
Wisconsin and 0.4% pregnant women did not receive any prenatal care. It 
can then be assumed that if an HIV test was offered late in a pregnancy, if 
the acceptance rate was at least 90%, most women would be tested for 
HIV prior to labor and delivery (Wisconsin Bureau of Family and Child 
Health, 2003). 
C. Labor and delivery 
If the woman has not been tested for HIV prior to labor and delivery (i.e. not offered test, 
no notation ofHIV test in chart, or refused the test), she is counseled and offered a rapid 
HIV test at this time. 
Physician responsibilities: The burden of testing lies with the providers at 
the time oflabor and delivery. Provider must determine if the woman has 
been tested for HIV. If not, the provider must counsel the woman about 
HIV, offer an HIV test, perform the test, record the result, link the woman 
to HIV care and treatment, and link the child to care and treatment. 
Patient responsibilities: Woman does not have any responsibility other 
than to consent or decline test. 
Advantages: Prenatal care provider does not need to do anything related to 
HIV since it will be taken care of at the time of delivery. Studies show 
that most women accept an HIV test when offered at the time of delivery. 
This will ensure that most cases of HIV are detected. 
Disadvantages: A woman may be newly infected and still not detectable 
by the test methodology being used. Woman may not consent to an HIV 
test. If found to be positive, a woman may not consent to or adhere to 
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treatment. Because testing is done at delivery, treatment options may be 
limited for the infant. 
Recommended by: ACOG recommends testing in labor and delivery if 
previous HIV testing has not been done at an earlier time or if testing has 
been refused prior to delivery. 
States that use: No state uses this strategy as a lone means of perinatal 
HIV testing. 
Does it work: Over 85% of pregnant women receive an HIV test prior to 
labor and delivery, therefore data to assess this strategy has been lacking 
(CDC, 2000) 
D. Newborn testing 
HIV testing of all newborns born to mothers who have not been tested for HIV infection. 
Physician responsibilities: Provider must determine if the newborn's 
mother has been tested for HIV prior to delivery. Any healthcare 
provider, not just the prenatal care provider, must keep accurate records 
and document in the patient's chart any HIV test and its result. If the 
newborn is found to have HIV antibodies, the provider must approach the 
mother to seek permission for treating the infant, and also to get the 
woman into care. 
Patient responsibilities: Woman is responsible to be aware of any 
previous HIV test that has been informed, where it was conducted and its 
result. Woman must seek and adhere to care and treatment for both herself 
and the infant if the newborn is found to be positive. 
Advantages: Cost-effective. Finds most HIV positive pregnant women 
through testing of the newborn. Time spent in the hospital, under 
supervision, is important for woman to adjust to the findings, find a care 
and treatment provider, and start on treatment. 
Disadvantages: Does not allow for treatment prior to delivery. Testing at 
delivery does not allow time for counseling or care decisions to be made. 
May be more upsetting to mother to find out this way. Infants rights may 
be violated. 
Recommended by: As part of their three-step approach to reducing 
perinatal HIV transmission, the American College of Obstetricians and 
Gynecologists (ACOG) recommend that "for infants whose mother's HIV 
status was not determined during pregnancy, the healthcare provider 
should educate the parents and recommend HIV testing for the newborn." 
However, they stop short of requiring mandatory testing of newborns. 
States that use: Currently, there are two states, Connecticut and New York 
that use this strategy as a part of their option to reduce perinatal HIV 
transmission. Providers in those states are required by law to perform 
newborn testing as soon as possible after birth. No consent or 
authorization is needed from the parents. In Indiana providers are 
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Methodology 
authorized by law to test a newborn if they feel that it is medically 
necessary and the mother has not undergone an HIV test. 
Does it work: In 1999, prior to enactment of the newborn testing law, 
New York reported a maternal testing rate of 69% and Connecticut 
reported a rate of31%. After enactment of the law the rate rose to 93% 
and 81%, respectively (Wolf, Lo, Gostin, 2004). 
In order to find a perinatal HIV testing policy that would work in Wisconsin, this paper 
first looked at the history of perinatal HIV testing and the strategies that are available. A 
decision analysis model was developed to compare the perinatal HIV test strategies reviewed. 
Variables in this model included strategy usage (percent of women who would test, percent of 
providers who would use), the general acceptability of the strategy by the public, the barrier 
testing imposes on care access (care deterrence rate), cost effectiveness, outcome effectiveness 
(does the strategy show find HIV-positive pregnant women), and is there an accountability 
mechanism, evaluation or assessment mechanism. 
This analysis was done using data obtained from published studies, surveillance data, and 
expert opinion for all variables for each strategy. Each strategy was then ranked using these data. 
Ranks were summed for each strategy to determine an overall rank for the strategy. Strategies 
with a higher rank (lower number) were included in the recommendations. Table I 0 summarizes 
the variables used and their sensitivity ranges and rank. Final Recommendations also took into 
account qualitative data such as social, ethical, legal, political and organizational reasons for 
offering or accepting an HIV test. Those qualitative reasons are listed in Table II & 12. 
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Table 10. Criteria for assessment of testing strategies 
Women Care Providers Public Cost 
Criteria would test Deterrence would use Acceptability effective? 
Strategy Rate Yes=1,No=O 
Approach+ % Rank % Rank % Rank % Rank 
No testing 10 3 0 1 77 2 31 3 0 
Selective 25 2 0.4 2 15 3 85 2 0.5 
Universal 90 1 0.4 2 90 1 88 1 1 
Offer ...... 
Voluntary 95 2 0 1 90 2 85 1 0.5 
Mandatory 100 1 1.5 2 100 1 64 2 1 
Consent__,. 
Opt-in 77 2 0 1 55 3 31 2 0.5 
Opt-out 98 1 0.4 2 79 1 68 1 1 
No consent 15 3 0.44 3 57 2 28 3 0 
Schedule--
Early 53 3 No data -- 88 3 77 1 0.5 
Late 21 4 No data -- 93 2 60 3 0.5 
Labor 95 1 No data -- 95 I 75 2 1.0 
Newborn 81 2 No data -- 77 4 45 4 0.5 
' (CDC, 1998) 
++ (Nakchbandi, Longenecker, Ricksecker, et.al., 1998; Jayaraman, Preiksaitis, Larke, 2003) 
+++ (Sherr, Bergenstrom, Hudson, 2000) 
++++(Pagnini, 2000, Mar/Apr; Johnson, Sorville, Wahl, et.al., 2003) 
Table 21. Reasons physicians chose not to offer HIV test (Maxwell, 2003) 
Language barriers 
Patient population at low risk for HIV 
Too time consuming 
Concern over offending the patient 
Patient enters into care late in their pregnancy 
HIV test takes too long 
Effective? Accountability 
O=not effective mechanism? 
5 =very effective Yes:1.No=O 
Scale Rank 
0 3 0 
2 2 0.5 
5 1 1 
4 2 0.5 
5 1 1 
4 2 1 
5 1 1 
3 3 0 
3 2 0.5 
3 2 0.5 
4 I I 
3 2 I 
Table 23. Reasons pregnant women chose not to get an HIV test (Aynalem, Kerndt, Hawkins, 2004) 
Fear of being labeled as sexually promiscuous 
Fear of being labeled as an injection drug user 
Denial about being infected 
Fatalism about life 
Fear of loss of emotional and financial support 
Lack of perceived risk for HIV infection 
Lack of spousal approval for HIV test 
Lack of knowledge about HlV 
Lack of linkage to medical care 
Fear of damage to provider relationship 
Feel that treatment is not proven 
Fear government will intervene 
Violation of bodily integrity (41h amendment) 
Violation of right to privacy (141h amendment} 
Fear of erosion of confidentiality 
Tested in the previous 6-months 
Insurance does not cover testing 
Fear insurance will be discontinued if found positive 
Caregiver/provider feels I am not at risk 
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Rank 
Score 
Total 
12 
12 
8 
9 
9 
11.5 
8 
14 
10 
12 
7 
13.5 
Discussion 
Women, especially those of childbearing age, continue to make up a significant 
percentage of people living with HIV in Wisconsin. In 2004, women accounted for 17% of 
residents living with HIV infection. Children who have HIV almost always acquire the virus by 
transmission from the mother. Despite a reduction in the numbers of children being born 
infected with HIV during the past decade, the CDC estimates that in 2005, 280-370 infected 
infants will be born in the United States. This underscores the need for effective strategies to 
ensure all pregnant women are tested for HIV, so that the woman knows her HIV status and if 
HIV -positive can obtain treatment for the disease and can prevent passing it on to her unborn 
children. 
The advent of successful treatment options for pregnant women to prevent mother to 
child (perinatal) HIV transmission we now have the opportunity to further reduce, if not 
eliminate, HIV disease in children born in Wisconsin. To do so, we must develop a consistent 
statewide strategy. This paper systematically reviews the history and options of perinatal HIV 
testing in order to recommend such a strategic policy. 
Why should I care? 
• HIV is a serious health threat to the mother and infant 
Although HIV may be considered by some as a chronic disease, it still remains a fatal 
disease. With early detection and appropriate intervention, the quality and duration of the life of 
children with HIV continues to improve. The median survival for infants not treated is six 
months or less whereas seventy percent of those who receive treatment survive past 6 years and 
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lead productive lives (Kamal and Rutlunore, 1997). Knowing the HIV status of the mother not 
only benefits the infant but also benefits the mother by getting the care and treatment needed so 
she can care for herself and her infant. 
• HIV effects the health of the public. 
A Washington Times survey conducted from February 12 to February 14,2005 reports that 
approximately 63% of those surveyed (864 physicians and 1339 non-physicians) said that they 
believe that compulsory HIV testing would improve the overall health of the US population 
(Kaiser Daily HIV I AIDS Report, February 22, 2005). 
• It saves taxpayers money 
By finding HIV infection in pregnant women it is estimated that 656 infants could be spared 
being born with HIV with a resulting cost savings of $105.6 million. If these costs were 
subtracted from the costs of implementing an HIV testing program the net savings is $38.1 
million. The cost-effectiveness and savings depends on the testing strategy employed, the region 
of the country and the seroprevalance of the region. A study conducted in Chicago states that 
when taking those criteria into account, even at a prevalence rate ofless than .01% routine 
screening of pregnant women would be cost-effective. In 2003 Wisconsin's prevalence rate for 
women was reported to be 0.04% (Immergluck, Cull, Schwartz, Elstein, 2000). 
What can be done? 
There are many strategies that can be used to increase detection of HIV infection among 
pregnant women. These strategies range from completely voluntary to completely mandatory 
testing options and within each strategy are subtle variations. Most states have policies, 
recommendations or guidelines to prevent perinatal transmission including 45 states that have 
28 
L 
policies on counseling/testing of pregnant women and 22 with policies on testing, monitoring or 
treatment of newborns. Of those 45 states who have policies or follow recommendations, only 
19 states have adopted state-mandated laws or regulations on HIV counseling and testing of 
pregnant women. 
Review and analysis of these strategies has shown that offering an HIV test to all 
pregnant women (universal) using an opt-out approach, both at the first prenatal visit and during 
labor and delivery, if EOt tested prior to delivery, offers the best chance of getting pregnant 
women tested for HIV. While the data did not clearly offer resolution to whether periantal HIV 
testing should be mandatory versus voluntary, issues of social acceptability, avoidance of 
prenatal care, violation of 4th and 14th amendment rights, and cost-effectiveness lead to the 
following recommendations: 
Recommendation 1. Strengthen pre-pregnancy HIV services, including Prevention and 
Partner Counseling and Referral Services (PCRS) 
Prior to pregnancy this is the single most effective means of identifYing women at high risk 
of exposure in low prevalence states such as Wisconsin. If women with HIV infection can be 
identified early and then treated the chances of transmitting the disease to their offspring is very 
low. 
Recommendation 2. Develop a standard or care for universal, routine (opt-out) HIV testing 
as part of the prenatal laboratory screen during a woman's first prenatal visit 
Primary emphasis for the elimination of perinatal HIV transmission in Wisconsin should be 
placed on the healthcare provider by the adherence to a provision of HIV testing as a routine part 
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of prenatal care, with notification and the right of refusal. Additionally, emphasis should be 
placed on maximizing the proportion of women participating in prenatal care during pregnancy. 
In doing so, an HIV test should be included in routine prenatal laboratory tests panels and 
offered to the woman at her first prenatal medical visit. Prior to doing any laboratory testing the 
prenatal healthcare provider will be required to counsel every patient on all tests included in the 
panel, including the HIV test. The woman would retain the right to decline any and all of the 
tests offered. Any declination will be noted in the patient chart. Acceptance of HIV testing will 
be signified by laboratory results noted in the patient chart. 
Recommendation 3. Offer HIV testing during the third trimester to those who've previously 
declined testing or those who at risk for HIV disease. 
In order to include women who may reconsider HIV testing, or women who continue to have 
risk for contracting HIV into their pregnancy, a health care provider should offer an HIV test in 
the third trimester of pregnancy. This would be at the discretion of the caregiver and the reasons 
detailed in the patient's chart. Declination of the offer ofHIV testing must be noted in the 
patient's chart. 
Recommendation 4. Require by law that HIV test results, or a statement of declination, be in 
a patients chart at the time of labor and delivery. 
If at the time of delivery there is no note of an HIV test results or specific refusal of an HIV 
test, the hospital in which the delivery is taking place has the authority to offer rapid HIV testing 
to the mother. Any expense incurred in doing so would be passed on to the prenatal caregiver. 
As the standard of care, the chart will have either test results or a statement of HIV test denial. If 
lacking at labor and delivery or during chart review, the hospital's record review authority may 
assess monetary penalties or privilege penalties. 
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Recommendation 5. Mandate Newborn HIV testing if the mother has not been tested for HIV 
Because pregnant women have the right to refuse all offers for an HIV test, a mechanism must in 
place to protect the child. Therefore, it is recommended that the hospital be required by law to 
test the newborn for HIV infection if there is no record of the mother having been tested. 
Conclusion 
Development and implementation of a pr;:rinatal HIV testing strategy in Wisconsin is 
essential to further reducing the numbers of infants born with HIV infection. Examination and 
analysis of the perinatal HIV testing strategies available has lead to recommendations of a 
strategy that will work in Wisconsin. Recognizing that prenatal prophylaxis and treatment for 
HIV disease is not I 00% effective, detecting HIV -positive pregnant women through the 
recommended strategy and then offering them treatment could potentially reduce MTC 
transmission ofHIV infection in Wisconsin, to 1.6%, or to one or no infants with HIV infection 
within a four year period (Schell, Hoxie, Steenberg, Maxwell, 2005). While this paper lays out 
the strategy most likely to be effective in Wisconsin, further development into an effective policy 
is needed. 
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Appendix A. Logic Model of How to Reduce Perinatal HIV Infection 
Continued Perinatal transmission of HIV 
The Problem *Treatment can reduce the rate of perinatal HIV transmission 
* In order for this to happen, pregnant women must know their HIV status by getting tested for HIV 
. 
*The goal of 0 transmission is within our reach in Wisconsin 
I 
I I I I 
Social barriers Ethical barriers Systems barriers 
*Stigma Legal barriers 
*Denial ""Access ""Denial of care *Language 
*Rejection *Targeting *Right to privacy *Insurance 
*No risk *provider-patient relationship "Bodily integrity *Low prevalence 
*Unconstitutional *Time 
*Knowledge 
*Long-term effects unknown I *Rapid test not available *Approval 
I I I I 
Stakeholders 
*Patients 
*Providers 
*Advocacy groups 
*State staff 
*Legislators 
*Media 
f---
r 
i 
F 
Change norms and influences Changing the system 
*Universal HIV testing *Develop standard of care 
*Routine HIV testing *Mandatory newborn HIV testing 
I 
Public Policy that supports health 
*Standard of Care 
*Law 
I 
Outcome No children born with HIV infection 
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